October 29, 2015
1 min read

Tagworks paper on pretargeting using click chemistry in vivo

In a recent paper in the Journal of Nuclear Medicine, Tagworks, in collaboration with Austrialian biotech company Avipep, describes an alternative radioimmunotherapy strategy based on separate administration of the tumor-homing agent and a fast clearing radioactive probe. This way, the unwanted high renal retention of low-molecular weight radiometal tumor-homing agents can be overcome.

The Tagworks and Avipep researchers show that a pretargeting strategy with a small protein may be an attractive approach in radioimmunotherapy to reduce kidney uptake while maintaining high tumor targeting. An effective tumor-targeting agent, a TAG72 diabody that had a high kidney uptake as a directly radiometal-labeled analog, showed complete retention of its properties upon TCO-modification. Administration of a radiometal-labeled tetrazine in a second step, showed efficient tumor uptake and most importantly low kidney uptake. This pretargeting strategy could be an important alternative platform, superseding the use of peptides and small proteins as metal-chelate conjugates for imaging and therapy.

Read the full paper: doi:10.2967/jnumed.115.159145


Curious about what we do? Get in touch!


About    Our Technology   Pipeline    Join us    News    Contact

T +31 85 800 8550

Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra